Find News

Filter articles

Showing 3531 to 3540 of 3632 results

India recommends compulsory licence for anti-cancer drug


The Health Ministry in India has recommended that a compulsory licence is issued for the manufacture of Bristol-Myers Squibb’s anti-cancer drug Sprycel (dasatinib), potentially opening the door to the sale of cheaper imitations.

PolyTherics completes Antitope takeover


UK biopharmaceuticals company PolyTherics has completed a takeover of Antitope, a provider of antibody engineering and immunogenicity screening services.

AIPPI 2013: Pharmaceutical products and the trademark hiccup


The annual International Association for the Protection of Intellectual Property conference in Helsinki has been assessing the potential problems for pharmaceutical companies trying to brand their medicinal products.

BioEconomy Academy launches in Bangkok


Law firm Rouse has teamed up with two organisations to open the BioEconomy Academy, an initiative aimed at boosting IP use and awareness in Thailand.

Amici submit brief to support Ambry in Myriad case


The American Civil Liberties Union and other groups have submitted an amici curiae brief in support of Ambry Genetics and Gene by Gene in their patent infringement cases with Myriad Genetics Inc.

Marks & Clerk UK promotes two to partnership


UK IP firm Marks & Clerk LLP has announced two of its attorneys will be joining the firm’s partnership.

Austria becomes first country to ratify Unified Patent Court agreement

Austria, EU27-08-2013

Austria has become the first country in the EU to ratify consent to the Unified Patent Court.

Miles & Stockbridge welcomes eight IP professionals


US law firm Miles & Stockbridge PC has continued the expansion of its IP practice with the addition of seven lawyers and one patent agent.

Eli Lilly bids to stop generics cutting Alimta exclusivity


Eli Lilly has begun its defence of a patent covering lung cancer drug Alimta against generic companies including Teva, Barr Laboratories and APP Pharmaceuticals.

Horizon Pharma settles Duexis case with Par Pharmaceuticals

US22-08-2013Legal developments

US-based Horizon Pharma Inc agreed on August 22 to settle its patent dispute over arthritis drug Duexis with generic maker Par Pharmaceutical Companies.

Showing 3531 to 3540 of 3632 results